Redhill Biopharma Total Revenue

The latest total revenue for RDHL is $9.5M as of June 2025. That compares with $3.7M in the prior-year period — up 157.6% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside Redhill Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, RDHL's total revenue moved from $3.7M to $9.5M — a 157.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Redhill Biopharma's operating scale or balance-sheet position.

Against Healthcare companies, RDHL currently prints $9.5M for total revenue, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Redhill Biopharma's growth, margins, and balance sheet.

A total revenue figure of $9.5M for RDHL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting RDHL's total revenue ($9.5M), review year-over-year change from $3.7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.